Skip to main content

Table 3 Prevalence of metabolic syndrome (MetS) and its criteria among subjects

From: Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia

 

All

Male

Female

 

Inpatients

Outpatients

P value

Inpatients

Outpatients

P value

Inpatients

Outpatients

P value

MetS prevalence:

         

ATP III-A

15.8

48.1

< 0.001

14.1

55.8

< 0.001

17.3

40.6

< 0.001

IDF

14.7

44.1

< 0.001

11.9

48.6

< 0.001

17.1

39.4

< 0.001

JASSO

9.1

33.2

< 0.001

13.6

45.8

< 0.001

5.1

20.2

< 0.001

MetS criteria prevalence:

         

Waist circumference

         

   Male ≥ 90 cm, female ≥ 80 cm

46.2

64.2

< 0.001

27.8

61.7

< 0.001

62.4

66.8

NS

   Male ≥ 85 cm, female ≥ 90 cm

34.9

59.0

< 0.001

42.3

73.8

< 0.001

28.4

43.8

< 0.001

BP (≥ 130/85 mmHg)

30.7

46.7

< 0.001

37.2

55.5

< 0.001

25.1

37.5

< 0.01

HDL (male < 40 mg/dl, female < 50 mg/dl)

25.5

31.8

< 0.05

22.7

28.9

NS

28.0

34.8

NS

Triglyceride (≥ 150 mg/dl)

11.2

40.6

< 0.001

13.2

50.2

< 0.001

9.4

31.0

< 0.001

HDL (< 40 mg/dl) and TG (≥ 150 mg/dl)

20.8

46.1

< 0.001

28.2

58.1

< 0.001

14.4

34.0

< 0.001

Glucose (≥ 100 mg/dl)

17.5

50.9

< 0.001

16.6

56.0

< 0.001

18.4

45.5

< 0.001

Glucose (≥ 110 mg/dl)

9.5

35.3

< 0.001

9.9

36.8

< 0.001

9.2

33.7

< 0.001

  1. All prevalences are expressed as a percentage (%) and were analyzed using the χ2 test comparing the reference group and the schizophrenic patients.
  2. ATP III-A = Adapted National Cholesterol Education Program Adult Treatment Panel; BP = blood pressure; IDF = International Diabetes Federation; JASSO = Japan Society for the Study of Obesity; HDL = high-density lipoprotein; NS = not significant.